


PHARMACEUTICAL 2017

CAMBREX CORP Rank 15 of 313







RealRate

PHARMACEUTICAL 2017

CAMBREX CORP Rank 15 of 313

The relative strengths and weaknesses of CAMBREX CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CAMBREX CORP compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 544% points. The greatest weakness of CAMBREX CORP is the variable Other Expenses, reducing the Economic Capital Ratio by 235% points.

The company's Economic Capital Ratio, given in the ranking table, is 185%, being 602% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	322,655
Cost of Goods Sold	0
Intangible Assets	55,123
Liabilities, Current	95,462
Liabilities, Non-Current	21,946
Other Assets	16,995
Other Compr. Net Income	-10,071
Other Expenses	327,791
Other Liabilities	89,030
Other Net Income	-6,461
Property and Equipment	217,092
Research and Development	14,292
Revenues	490,644
Selling, General and Administrative Expense	60,422

Output Variable	Value in 1000 USD
Assets	611,865
Liabilities	206,438
Expenses	402,505
Stockholders Equity	405,427
Net Income	81,678
Comprehensive Net Income	76,642
Economic Capital Ratio	185%

